EUVIMEDOdkrijte EUVIMED
Crossref

Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells

Hong Xu, Shujun Zeng, Yingmei Wang, Tong Yang, Minmin Wang, Xuan Li, Yejun He, Xin Peng, Xia Li, Qing Qiao, Jing Zhang iD

The Journal of Pathology · 2023

DOI: 10.1002/path.6167 ↗

At a glance

Journal article in The Journal of Pathology, 2023. Written by Hong Xu and 10 co-authors. Institution: State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, The Fourth Military Medical University, Xi'an, PR China. Major MEDLINE topics: Paclitaxel, Ovarian Neoplasms. Cited 15 times so far (Crossref); 65 references. Funded by: National Natural Science Foundation of China.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Therapeutic resistance is a notable cause of death in patients with ovarian carcinoma. Polyploid giant cancer cells (PGCCs), commonly arising in tumor tissues following chemotherapy, have recently been considered to contribute to drug resistance. As a type III deacetylase, Sirtuin1 (SIRT1) plays essential roles in the cell cycle, cellular senescence, and drug resistance. Accumulating evidence has suggested that alteration in its subcellular localization via nucleocytoplasmic shuttling is a critical process influencing the functions of SIRT1. However, the roles of SIRT1 subcellular localization in PGCC formation and subsequent senescence escape remain unclear. In this study, we compared the differences in the polyploid cell population and senescence state of PGCCs following paclitaxel treatment between tumor cells overexpressing wild‐type SIRT1 (WT SIRT1) and those expressing nuclear localization sequence (NLS)‐mutated SIRT1 (SIRT1 NLSmt ). We investigated the involvement of cytoplasmic SIRT1 in biological processes and signaling pathways, including the cell cycle and cellular senescence, in ovarian carcinoma cells' response to paclitaxel treatment. We found that the SIRT1 NLSmt tumor cell population contained more polyploid cells and fewer senescent PGCCs than the SIRT1‐overexpressing tumor cell population. Comparative proteomic analyses using co‐immunoprecipitation (Co‐IP) combined with liquid chromatography–mass spectrometry (LC‐MS)/MS showed the differences in the differentially expressed proteins related to PGCC formation, cell growth, and death, including CDK1 and CDK2, between SIRT1 NLSmt and SIRT1 cells or PGCCs. Our results suggested that ovarian carcinoma cells utilize polyploidy formation as a survival mechanism during exposure to paclitaxel‐based treatment via the effect of cytoplasmic SIRT1 on PGCC formation and survival, thereby boosting paclitaxel resistance. © 2023 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

PaclitaxelOvarian NeoplasmsFemaleHumansSirtuin 1ProteomicsCell Line, TumorCarcinoma, Ovarian EpithelialPolyploidy

Author keywords

chemoresistanceovarian carcinomapolyploid giant cancer cellsirtuin1subcellular localization

Substances

PaclitaxelSirtuin 1SIRT1 protein, human

Authors and institutions

  • State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, The Fourth Military Medical University, Xi'an, PR China.
  • Department of Pathology, No. 971 Hospital of People's Liberation Army Navy, Qingdao, PR China.
  • School of Basic Medicine, The Fourth Military Medical University, Xi'an, PR China.
  • State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, The Fourth Military Medical University, Xi'an, PR China.
  • Department of General Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, PR China.

ORCID profiles: Jing Zhang

Funding

  • National Natural Science Foundation of China

Cite

APA

Xu, H., Zeng, S., Wang, Y., Yang, T., Wang, M., Li, X., He, Y., Peng, X., Li, X., Qiao, Q., & Zhang, J. (2023). Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells. The Journal of Pathology. https://doi.org/10.1002/path.6167

Vancouver

Xu H, Zeng S, Wang Y, Yang T, Wang M, Li X, et al. Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells. The Journal of Pathology. 2023. doi:10.1002/path.6167

BibTeX
@article{Xu2023,
  author = {Xu, Hong and Zeng, Shujun and Wang, Yingmei and Yang, Tong and Wang, Minmin and Li, Xuan and He, Yejun and Peng, Xin and Li, Xia and Qiao, Qing and Zhang, Jing},
  title = {Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6167}
}
Start for free →